Xenova Group plc immediately expects to commence the first of two planned Phase III trials for TransMID, a candidate for brain cancer. (BioWorld Today)

With SPA Agreement, Xenova Plans Two TransMID Phase IIIs

May 12, 2004

By Kim Coghill

Xenova Group plc immediately expects to commence the first of two planned Phase III trials for TransMID, a candidate for brain cancer. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...